Harrow PE ratio HROW

Share price divided by earnings per share over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 45.7×; Nov 2021
8-year median: 24.9×
8-year range: 10.0× to 45.7×
Peer median: 12.8×

Harrow has no meaningful PE ratio today: it lost $0.99 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Nov 2021, at 45.7×.

On the days it had one over the last 8 years, its median was 24.9×, from 10.0× in Mar 2019 to 45.7× in Nov 2021.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	45.7×	19.4×	45.7×
2020	10.4×	10.4×	11.9×
2019	13.1×	10.0×	13.1×

Against its peers

Companies in Drug Manufacturers - General nearest Harrow's size, closest first, today.

Company	PE ratio
HROWHarrow	n/m
AMPHAmphastar Pharmaceuticals	14.8×
OMEROmeros	10.9×
ABUSArbutus Biopharma	5.4×
PCRXPacira BioSciences	104×
ANABAnaptysbio	10.7×
COLLCollegium Pharmaceutical	18.5×
PAHCPhibro Animal Health	15.9×
ANIPANI Pharmaceuticals	15.4×
CRMDCorMedix	3.7×
ZVRAZevra Therapeutics	10.5×
Peer median	12.8×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Harrow

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.